Go Deep
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 22,216 | 12.2 | 1.43 | 0.00 | 130.05 |
| Sep 2026 | 22,216 | 12.2 | 1.43 | 0.00 | 130.05 |
| Sep 2026 | 22,216 | 12.2 | 1.43 | 0.00 | 130.05 |
| Oct 2026 | 25,846 | 11.6 | 1.36 | 0.00 | 123.95 |
| Oct 2026 | 25,029 | 11.0 | 1.29 | 0.00 | 117.10 |
Par Drugs and Chemicals Limited Quarterly Results
| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 196,108,000.0 | 293,395,000.0 | 286,589,000.0 | 260,464,000.0 |
| Net Profit | 8,536,000.0 | 47,972,000.0 | 41,296,000.0 | 33,281,000.0 |
| EPS | 0.7 | 3.9 | 3.4 | 2.7 |
Par Drugs and Chemicals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,027,985,000.0 | 1,005,460,000.0 | 951,066,000.0 | 950,951,000.0 | — |
| Net Profit | 131,085,000.0 | 133,579,000.0 | 145,010,000.0 | 113,341,000.0 | — |
| EPS | — | 10.9 | 11.8 | 9.2 | 7.5 |
Par Drugs and Chemicals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,292,124,000.0 | 1,193,901,000.0 | 1,016,111,000.0 | 888,679,000.0 | — |
| Total Liabilities | 172,278,000.0 | 204,152,000.0 | 159,791,000.0 | 176,296,000.0 | — |
| Total Equity | 1,119,846,000.0 | 989,749,000.0 | 856,320,000.0 | 712,383,000.0 | — |
Owes vs Owns
Par Drugs and Chemicals Limited owed ₹0.13 for every ₹1 it owned in Mar 2026, down from ₹0.20 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.13× | 0.17× | 0.16× | 0.20× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Par Drugs and Chemicals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 32.4%Receivables 9.3%Inventory 4.2%Fixed assets (tangible) 28.8%Long-term investments 21.0%Other assets 4.4%
How it's funded — Mar 2026
Payables 6.3%Other liabilities 7.0%Shareholders' equity 86.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 41.8 | 27.6 | 36.7 | 22.2 |
| Receivables | 12.0 | 16.7 | 13.7 | 17.0 |
| Inventory | 5.4 | 6.1 | 4.2 | 5.4 |
| Fixed assets (tangible) | 37.2 | 38.9 | 41.3 | 38.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 27.1 | 25.1 | 0.0 | 0.0 |
| Other assets | 5.7 | 5.0 | 5.7 | 5.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 8.2 | 10.9 | 5.4 | 8.1 |
| Other liabilities | 9.0 | 9.5 | 10.6 | 9.5 |
| Shareholders' equity | 112.0 | 99.0 | 85.6 | 71.2 |
| Net tangible assets | 112.0 | 99.0 | 85.6 | 71.2 |
Par Drugs and Chemicals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 164,321,000.0 | 161,602,000.0 | 202,489,000.0 | 133,771,000.0 | — |
| Investing Activities | -21,664,000.0 | -252,370,000.0 | -58,381,000.0 | -73,381,000.0 | — |
| Financing Activities | 0.0 | 0.0 | 0.0 | -24,000.0 | — |